Skip to main content
Nathaniel Jacobson headshot

Nathaniel Jacobson

ASA, FSA
Senior Consulting Actuary
New York, NY, US
Nathaniel Jacobson is an associate actuary with the New York office of Milliman. He joined the firm in 2017.
Download bioDownload

Experience

Nathaniel has provided consulting services to a broad range of clients, including health plans, pharmaceutical companies, hospital systems, and other healthcare providers.

Nathaniel has extensive experience with the following:

  • Assisting clients with individual and small group market federal and state filings of premium rates under the Affordable Care Act
  • Assisting pharmaceutical clients with market analysis and payer launch strategy
  • Analyzing healthcare utilization, costs, and trends using large commercial and Medicare databases
Publications

Read their latest work

Article

Why voluntary alignment may not meet your ACO’s expectations

10 November 2022 - by Charlie Mills, Nathaniel Jacobson, Noah Champagne
We explore the voluntary alignment requirements for global/professional direct contracting and ACO REACH, along with considerations for beneficiary engagement.
Article

Health coverage in the Gig Economy – Experience from several countries

02 February 2022 - by Somya Bansal, Joanne Buckle, Diana Dodu, Nathaniel Jacobson, Alexander Krauskopf, Monika Lis, Yunzi Xia, Rong Yi
Health insurance companies must adapt and innovate their product offerings to appeal to the expectations of freelancers and on-demand gig workers.
Article

The role of pharmacy benefits on ACA market premiums: Decomposing premium trends in the individual and small group markets

27 October 2020 - by Dane Hansen, Gabriela Dieguez, Nathaniel Jacobson, Emily DeAngelis
This paper examines the role of prescription drug costs in premium increases in the Patient Protection and Affordable Care Act individual and small group marketplaces.
Article

Site of Service and Cost Dispersion of Infused Drugs

11 December 2019 - by Gabriela Dieguez, Tyler Engel, Nathaniel Jacobson
This paper examines the cost dispersion of one infused disease-modifying therapies treatment, ocrelizumab, by site of service for patients with commercial insurance, a major insurance segment for multiple sclerosis patients.